When performing CCK-8 assays on the HCC95 cell line (concentration gradient 0–20 mM), no obvious dose-response trend was observed. Are there any literature reports supporting the use of Zenocutuzumab (HY-P99507, MCE) in HCC95 or HCC series cell lines? Additionally, is HCC95 known to harbor the NRG1 fusion gene? If there are no relevant reports, should the cell line be replaced, or should NRG1 mRNA/protein expression levels be detected first to confirm its suitability as an experimental model for Zenocutuzumab?
No literature reports were found regarding the use of this antibody in HCC95 or the HCC cell line series. The literature explicitly states that Zenocutuzumab can inhibit cells with NRG1 fusion genes, and its mechanism of action differs from that of small-molecule inhibitors. No literature support was found for NRG1 fusion in HCC95. Therefore, you may consider using a different cell line (References: PMID: 35135829; Poster: The HER2×HER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions from Memorial Sloan Kettering Cancer Center), or add detection indicators to measure the mRNA or protein expression levels of NRG1 to confirm its expression status. The answer to this question is provided by MedChemExpress Technical Support.
- Badges
- Science topic